Gain Therapeutics will be providing an update on our lead compound in development for GBA-associated Parkinson’s disease, GT-02287 at the Jefferies Global Healthcare Conference. Recent

1. What initially sparked your interest in neuroscience? Science has always interested me. Even as a young child I wanted to be a scientist or

What is PROTAC? PROTAC, which is an acronym for proteolysis targeting chimera, is a class of heterobifunctional molecules that can be used to target specific proteins for degradation

How do allosteric drugs compare to more traditional orthosteric drugs? Orthosteric drugs are compounds that bind to the active site of an enzyme. In order

What are prion diseases? Prion diseases are a group of neurodegenerative disorders that affect humans and other mammals. The most recognizable prion diseases are bovine

The presentation by Professor Zoe Cournia, who is at the Biomedical Research Foundation Academy of Athens in Greece, was about the power of supercomputing and

Professor Ricardo Feldman, who is from the University of Maryland School of Medicine, gave a presentation about Gain Therapeutics STAR molecules for the treatment of

Professor Tiago Outeiro who is Professor of Aggregopathies and Director of the Department of Experimental Neurodegeneration at the University Medical Center in Gottingen, Germany, and

Presenting at Gain Therapeutics R&D Day, Manolo Bellotto, Ph. D elaborated on the Broad Application of Gain Therapeutics’ Structurally Targeted Allosteric Regulators (STARs). See the

Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about discovering Novel Allosteric Targets by Combining Advances in Big Data and Computational Technology.

Manolo Bellotto, Ph. D gave an overview of Gain Therapeutics GBA program during Gain Therapeutics R&D Day. He explained how GBA program targets beta-glucocerebrosidase, or

During Gain Therapeutics R&D Day, Samuel Broder, MD shares his perspective on Neuroscience and Beyond. The title of his presentation was “The Role of Allosteric

Q: Dr. Xavier Barril, what was the evolution of your career?  A: I received my PhD in Biochemistry from the University of Barcelona in 2001

We have initially applied See-TX to selective protein misfolding diseases and have targeted lysosomal enzyme, to address the unmet medical needs of rare and neurodegenerative

What is allostery? Allo comes from the Greek allos which meaning “other.” Allosteric binding describes a ligand that binds a protein at a target site

When was Alzheimer’s disease discovered? Alzheimer’s disease as we know it was first described by Dr. Alois Alzheimer, a German doctor, in 1906. He was

Alpha-synuclein is a neuronal protein that regulates trafficking and neurotransmitter release. Aggregation of alpha-synuclein is associated with the formation of lewy bodies, which are protein

Krabbe disease is a devastating disease that belongs to the Leukodystrophy disease family. These diseases are characterized by defects in the myelin, an insulating layer

Gaucher Disease and Parkinson’s Disease are two distinctly different diseases in terms of their onset, symptoms, and prognosis. Despite these differences these diseases have one

Discovering treatments for patients that currently have no available disease-modifying options is the priority of Gain Therapeutics. Specifically, there is a large unmet need for

Enzyme Targeting: Over the last few years, diseases caused by dysfunctional or missing enzymes have been treated with a type of therapy called enzyme replacement

Gain Therapeutics targeting allosteric sites: Traditional small molecule drugs work by targeting an active binding site. Gain Therapeutics is focused on targeting allosteric binding sites,

Why is the AlphaFold DataBase exciting? DeepMind created the artificial intelligence system, AlphaFold, to predict the three-dimensional (3D) structure of thousands of proteins and compiled

What is DeepMind? Deepmind AlphaFold protein folding structure prediction: DeepMind is a company that combines a variety of disciplines to develop artificial intelligence (AI) technology

Genetic mutations are one of the most common causes of serious diseases. When genes are mutated it can affect the function of proteins which oftentimes

Designing therapeutics that target cellular proteins can be difficult due to the lack of specific binding sites or the potential for disrupting the normal protein

Parkinson’s Disease is among the most common degenerative brain disorders, affecting millions of people each year in the United States alone. We know that the